ATE397066T1 - Methode zur bildung einer subtrahierten cdna bank und ihre verwendung - Google Patents

Methode zur bildung einer subtrahierten cdna bank und ihre verwendung

Info

Publication number
ATE397066T1
ATE397066T1 AT05028213T AT05028213T ATE397066T1 AT E397066 T1 ATE397066 T1 AT E397066T1 AT 05028213 T AT05028213 T AT 05028213T AT 05028213 T AT05028213 T AT 05028213T AT E397066 T1 ATE397066 T1 AT E397066T1
Authority
AT
Austria
Prior art keywords
stranded
double
subtracted
cdna
cdna library
Prior art date
Application number
AT05028213T
Other languages
English (en)
Inventor
Paul B Fisher
Hongping Jiang
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/143,576 external-priority patent/US5643761A/en
Priority claimed from US08/316,537 external-priority patent/US6051376A/en
Application filed by Univ Columbia filed Critical Univ Columbia
Application granted granted Critical
Publication of ATE397066T1 publication Critical patent/ATE397066T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1072—Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
AT05028213T 1993-10-27 1994-10-24 Methode zur bildung einer subtrahierten cdna bank und ihre verwendung ATE397066T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/143,576 US5643761A (en) 1993-10-27 1993-10-27 Method for generating a subtracted cDNA library and uses of the generated library
US08/316,537 US6051376A (en) 1994-09-30 1994-09-30 Uses of mda-6

Publications (1)

Publication Number Publication Date
ATE397066T1 true ATE397066T1 (de) 2008-06-15

Family

ID=26841189

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05028213T ATE397066T1 (de) 1993-10-27 1994-10-24 Methode zur bildung einer subtrahierten cdna bank und ihre verwendung

Country Status (10)

Country Link
US (4) US6720408B2 (de)
EP (3) EP1329509A3 (de)
JP (2) JP4145953B2 (de)
KR (1) KR100355111B1 (de)
AT (1) ATE397066T1 (de)
AU (1) AU695540B2 (de)
CA (1) CA2174354C (de)
DE (1) DE69435103D1 (de)
DK (1) DK1650303T3 (de)
WO (1) WO1995011986A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU692794B2 (en) * 1993-08-30 1998-06-18 Baylor College Of Medicine Senescent cell-derived inhibitors of DNA synthesis
EP1329509A3 (de) * 1993-10-27 2003-10-15 The Trustees of Columbia University in the City of New York Methode zur Bildung einer subtrahierten cDNA Bank und ihre Verwendung
ES2233943T3 (es) * 1994-05-24 2005-06-16 Baylor College Of Medicine Mimeticos de inhibidores de la sintesis de dna derivados de celulas senescentes.
US5710137A (en) * 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
WO1998028425A1 (en) * 1996-12-23 1998-07-02 Schering Corporation Mammalian cytokine related to il10
US6071696A (en) * 1996-12-30 2000-06-06 The Trustees Of Columbia University In The City Of New York Method of producing a temporally spaced subtracted (TSS) CDNA library and use thereof to monitor differentiation
US6190909B1 (en) * 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
US6399334B1 (en) * 1997-09-24 2002-06-04 Invitrogen Corporation Normalized nucleic acid libraries and methods of production thereof
US6410507B1 (en) 1997-12-24 2002-06-25 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
AU2010699A (en) * 1997-12-24 1999-07-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for theiruse
US6379951B1 (en) 1997-12-24 2002-04-30 Corixa Corporation Compounds for immunotherapy of breast cancer and methods for their use
US6432707B1 (en) 1997-12-24 2002-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO1999037774A2 (en) * 1998-01-26 1999-07-29 Genquest, Inc. Differentiation-associated sequences and methods of use therefor
WO1999037777A2 (en) * 1998-01-26 1999-07-29 Genquest, Inc. Differentiation-associated sequences and methods of use therefor
US6413717B1 (en) * 1998-03-18 2002-07-02 Corixa Corporation Methods for indentifying anti-cancer agents
AU4406699A (en) * 1998-05-15 1999-12-06 Paul B. Fisher Differentiation-associated sequences and methods of use therefor
AU2342900A (en) * 1998-09-23 2000-05-01 Cleveland Clinic Foundation, The Novel interferon stimulated and repressed genes
US6468758B1 (en) 1998-09-23 2002-10-22 Corixa Corporation Compositions and methods for ovarian cancer therapy and diagnosis
DE60038508T2 (de) * 1999-07-15 2009-04-30 Introgen Therapeutics Inc., Austin Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7
EP1254155A4 (de) * 2000-01-26 2003-06-18 Univ Vanderbilt Mob-5/hmob-5 als diagnostisches markierungsmittel
DE10003653A1 (de) * 2000-01-28 2001-08-09 Thorsten Petrich Vektorkonstrukte zur gentherapeutisch vermittelten Radioiodtherapie entdifferenzierter und medullärer Schilddrüsen-Karzinome sowie nicht-thyreoidaler Tumore und ihrer Metastasen
US7229822B1 (en) 2000-02-29 2007-06-12 Univ Columbia Melanoma differentation associated gene-5 and vectors and cells containing same
US6841362B1 (en) 2000-02-29 2005-01-11 The Trustees Of Columbia University In The City Of New York Melanoma differentiation associated gene-7 promoter and uses thereof
WO2002045737A2 (en) * 2000-12-07 2002-06-13 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
ATE501251T1 (de) 2001-01-25 2011-03-15 Evolva Ltd Zellbibliothek
US8008459B2 (en) 2001-01-25 2011-08-30 Evolva Sa Concatemers of differentially expressed multiple genes
US6902930B2 (en) 2001-08-29 2005-06-07 Vanderbilt University Human Mob-5 (IL-24) receptors and uses thereof
IL164214A0 (en) 2002-04-11 2005-12-18 Zymogenetics Inc Use of interleukin-24 to treat ovarian cancer
AU2003274963A1 (en) * 2002-12-23 2004-07-29 The Trustees Of Columbia University In The City Of New York Mda-7 and free radicals in the treatment of cancer
US8034790B2 (en) 2003-12-01 2011-10-11 Introgen Therapeutics Use of MDA-7 to inhibit pathogenic infectious organisms
US20080026410A1 (en) * 2004-12-02 2008-01-31 Antonia Vlahou Biomarkers for Bladder Cancer
JPWO2006093082A1 (ja) 2005-03-01 2008-08-07 和光純薬工業株式会社 サブトラクション・ポリヌクレオチドの取得方法
WO2008073615A2 (en) * 2006-11-03 2008-06-19 The Trustees Of Columbia University In The City Of New York N-glycosylation mutant of melanoma differentiation associated gene-7
EP2571991A1 (de) 2010-05-20 2013-03-27 Evolva SA Verfahren zur herstellung von isoprenoidverbindungen in hefe
JP6667790B2 (ja) * 2014-09-19 2020-03-18 国立大学法人京都大学 Ｔ細胞リンパ腫の検査方法
JP6973073B2 (ja) * 2015-11-06 2021-11-24 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CN108884159A (zh) 2015-11-07 2018-11-23 茂体外尔公司 用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
CA3046961A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0212285A1 (de) * 1985-07-29 1987-03-04 Arthur A. Gottlieb Herleitung und Verwendung ausgewählter Genprodukte
US4876187A (en) * 1985-12-05 1989-10-24 Meiogenics, Inc. Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences
WO1988007585A1 (en) * 1987-04-02 1988-10-06 Genelabs, Incorporated Equal-abundance transcript composition and method
DE3722958A1 (de) * 1987-07-11 1989-01-19 Heinrich Dr Klefenz Verfahren zur identifizierung und/oder isolierung spezifischer molekuele bzw. molekuelpopulationen
US6107023A (en) * 1988-06-17 2000-08-22 Genelabs Technologies, Inc. DNA amplification and subtraction techniques
JPH04502107A (ja) * 1988-12-07 1992-04-16 ザ・ジェネラル・ホスピタル・コーポレーション 挿入を有するかまたは欠失に相当するｄｎａの豊富化およびクローニングの方法
AU6646190A (en) * 1989-10-16 1991-05-16 Genelabs Technologies, Inc. Non-specific dna amplification
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US5643761A (en) 1993-10-27 1997-07-01 The Trustees Of Columbia University In The City Of New York Method for generating a subtracted cDNA library and uses of the generated library
EP1329509A3 (de) 1993-10-27 2003-10-15 The Trustees of Columbia University in the City of New York Methode zur Bildung einer subtrahierten cDNA Bank und ihre Verwendung
US6051376A (en) 1994-09-30 2000-04-18 The Trustees Of Columbia University In The City Of New York Uses of mda-6
US5710137A (en) 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
WO1998028425A1 (en) 1996-12-23 1998-07-02 Schering Corporation Mammalian cytokine related to il10
US6190909B1 (en) 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
US6413717B1 (en) 1998-03-18 2002-07-02 Corixa Corporation Methods for indentifying anti-cancer agents
DE60038508T2 (de) 1999-07-15 2009-04-30 Introgen Therapeutics Inc., Austin Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US20030082140A1 (en) 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
US20080026410A1 (en) * 2004-12-02 2008-01-31 Antonia Vlahou Biomarkers for Bladder Cancer

Also Published As

Publication number Publication date
CA2174354C (en) 2011-03-29
AU8088394A (en) 1995-05-22
EP1329509A2 (de) 2003-07-23
EP0730659A1 (de) 1996-09-11
KR960706565A (ko) 1996-12-09
US20090246272A1 (en) 2009-10-01
US20020183509A1 (en) 2002-12-05
EP1650303B1 (de) 2008-05-28
JP2007300928A (ja) 2007-11-22
JP4205136B2 (ja) 2009-01-07
WO1995011986A1 (en) 1995-05-04
JPH09507021A (ja) 1997-07-15
AU695540B2 (en) 1998-08-13
CA2174354A1 (en) 1995-05-04
EP0730659A4 (de) 1999-03-31
DK1650303T3 (da) 2008-09-08
EP1329509A3 (de) 2003-10-15
US6720408B2 (en) 2004-04-13
JP4145953B2 (ja) 2008-09-03
US20030225025A1 (en) 2003-12-04
DE69435103D1 (de) 2008-07-10
US20110136224A1 (en) 2011-06-09
EP1650303A3 (de) 2006-05-10
US7507792B2 (en) 2009-03-24
EP1650303A2 (de) 2006-04-26
KR100355111B1 (ko) 2003-03-03

Similar Documents

Publication Publication Date Title
ATE397066T1 (de) Methode zur bildung einer subtrahierten cdna bank und ihre verwendung
DE69900949D1 (de) Dns amplifizierung aus einzelnen zellen
DE69837913D1 (de) Verfahren zur vervielfältigung von nukleinsäure
WO1999014375A3 (en) Dna typing by mass spectrometry with polymorphic dna repeat markers
ATE382711T1 (de) Verfahren zur bestimmung des methylierungsgrades von bestimmten cytosinen in genomischer dna im sequenzkontext 5'-cpg-3'
DE60116651D1 (de) Methode zur amplifizierung und möglicher charakterisierung von nukleinsäuren
ATE239090T1 (de) Methode zum generieren von einzelsträngigen dna molekülen
WO2001071042A3 (en) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
JP2003524416A5 (de)
EP1961826A3 (de) Verfahren zur direkten Sequenzierung von Nukleinsäuren
BR0308134A (pt) análise rápida das variações em um genoma
JP2007517497A (ja) 標的核酸配列の検出のためのｏｌａベースの方法
CA2421767A1 (en) Method and kit for determining human geographic or population origin
WO2005118847A1 (en) Detection of target nucleotide sequences using an asymmetric oligonucleotide ligation assay
CA2477574A1 (en) Melting temperature dependent dna amplification
ATE361377T1 (de) Leistungstarke verknüpfung von nukleinsäuresegmenten
AU769759B2 (en) Allele frequency differences method for phenotype cloning
OA11358A (en) Primers for obtaining highly informative DNA markers.
WO2003060160A3 (en) Verification of fish origin based on nucleic acid pattern recognition
ATE278036T1 (de) Verfahren zur analyse der dna-methylierung unter verwendung von fluoreszenzpolarisation
Schmerer Reduction of shadow band synthesis during PCR amplification of repetitive sequences from modern and ancient DNA
ATE165870T1 (de) Verfahren zur amplifizierung und/oder nachweis einer nukleinsäuresequenz, nachweisreagenz und deren verwendungen
Langö et al. Simultaneous analysis of STR and VNTR polymorphisms
Berschick et al. Analysis of the short tandem repeat polymorphism TC 11 (HUMTH01): allele frequencies and family studies
Çakir et al. Distribution of amplified fragment length polymorphism D1S80 alleles in Turkish population

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties